Physician profile
Dwayne T Daugherty
NPI 1861493637
$2,798.47
in general payments reported to CMS, 2019-2025
31 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $169 · 2021: $447 · 2022: $430 · 2023: $382 · 2024: $480 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $385.29 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $288.91 | 2019-2025 | Evenity, Prolia |
| Abbvie INC. | $284.64 | 2019-2025 | |
| Novo Nordisk INC | $267.24 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $190.18 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $167.07 | 2019-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $165.04 | 2021-2024 | |
| Glaxosmithkline, LLC. | $129.61 | 2021-2025 | Arexvy, Shingrix |
| Pfizer INC. | $125.96 | 2019-2023 | |
| Inspire Medical Systems, INC. | $122.79 | 2024-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $93.05 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.65 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $64.08 | 2021-2023 | Steglatro, Belsomra |
| Dexcom, INC. | $45.07 | 2024-2025 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $41.26 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $40.60 | 2025 | General - Pain Management |
| Almatica Pharma LLC | $32.36 | 2021 | |
| Allergan, INC. | $29.99 | 2020 | |
| Optinose US, INC. | $24.64 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.43 | 2023 | Gvoke Hypopen |
| Welch Allyn | $22.83 | 2019 | |
| Exact Sciences Corporation | $22.09 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $20.22 | 2025 | |
| Linus Health, INC. | $20.16 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.15 | 2024 | Voquezna |
| Emmaus Medical, INC. | $17.84 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.44 | 2025 | Rexulti |
| Echosens North America, INC. | $16.22 | 2024 | Fibroscan |
| Amneal Pharmaceuticals LLC | $15.98 | 2023 | Unithroid |
| Abbott Laboratories | $15.44 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwayne Daugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.